Informizely customer feedback surveys

[Skip to content]

Southern Health
Search our Site

Reach

SANOFI

Outcomes in insulin naïve patients with uncontrolled Type 2 diabetes

The aim of this study is to evaluate the possible risks and the effectiveness of starting insulin therapy with Toujeo insulin when used in combination with other diabetes medications. This will be compared to starting insulin therapy with other commercially available "standard of care" basal insulin also used in combination with other diabetes medication.


What does it involve?

Before taking part in the study a full medical history and examination must be taken to ensure that it is safe for you to take part. If eligible for the study you will be treated for 52 weeks with one of the following:

1. Toujeo (insulin glargine)

2. Available "standard of care" insulin

You will continue to take your other non-insulin glucose-lowering medication if appropriate. 

The study consists of 6 clinic visits where we will take blood samples. You must fast for 8 hours before clinic visits.

Overall the duration of the study for each patient is approximately 53 weeks and comprises 3 periods: a 1-week screening period, a 26-week treatment period, and a 26-week extension period.


Inclusion Criteria
  • Patients with Type 2 diabetes insufficiently controlled with current standard of care medication


To refer potential participants or to request further information, please contact the research team:

Email: Chantelle.moorbey@southernhealth.nhs.uk

Tel: 02380 475 258

I would like to:

Return to Diabetes Studies

Return to Current Studies

Telephone the Research Team on 02380475258

Email the Research Team